Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0048—Eye, e.g. artificial tears
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/38—Cellulose; Derivatives thereof

Definitions

• US2011/0160214 relates to compositions and methods for achieving cosmetic eye whitening which utilize low concentrations of selective a-2 adrenergic receptor agonists.
• Tramadol is a centrally acting synthetic analgesic used to treat moderate to moderately- severe pain.
• the methods using the compounds described herein may be used to treat an individual wherein the redness results from episodic irritation.
• the methods using the compounds described herein may be used for relief of redness of the eye due to minor eye irritations.
• the administration may optionally be by injection around or into the eye e.g. intra vitreal or subconjunctival or sub tenon.
• compositions for use in the present invention may include the compound at a
• concentration from between about 0.01 % to about 2% weight by volume, or more.
• treatment includes combination treatments and therapies, in which two or more treatments or therapies are combined, for example, sequentially or simultaneously.
• the agents when administered sequentially, can be administered at closely spaced intervals (e.g., over a period of 5-10 minutes) or at longer intervals (e.g., 1 , 2, 3, 4 or more hours apart, or even longer periods apart where required), the precise dosage regimen being commensurate with the properties of the therapeutic agent(s).
• polyol thus includes short-chain molecules, including diols and triols, as well as longer-chain, higher molecular weight molecules with large or even indeterminate numbers of hydroxyl groups. Mixtures of polyols are equally possible. Examples of suitable polyols include sugars, sugar alcohols, sugar acids and uronic acids. Preferred sugar alcohols include mannitol and sorbitol. Short-chain polyols such as glycerol or propylene glycol are also very useful in these formulations, glycerol being a particularly suitable component in this regard. Mixtures of glycerol with other polyols, such as glycerol/sorbitol and glycerol/propylene glycol, are also found to be particularly useful.
• Emulsions and gels of various compounds may also be included.
• Natural tears contain lipids, and analogous compounds may be used in artificial tears.
• Phospholipids, particularly anionic phospholipids may be included (both of the
• Some artificial tears formulations may contain hydrocarbons, such as white petrolatum, mineral oil and white soft paraffin, although such materials are in general more appropriate to corresponding eye lubricant ointment formulations.
• the artificial tears should also be formulated to have a pH and osmolality compatible with the eye.
• the compositions will have a pH in the range of about 6.8 to 7.8.
• the artificial tears could have a pH slightly outside this range, so that as the artificial tears change pH in use, towards that of the eye, their effective viscosity increases.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Inorganic Chemistry (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Ophthalmology & Optometry (AREA)

Applications Claiming Priority (4)

Publications (1)

Family

ID=47225479

Family Applications (1)

Country Status (2)

Cited By (2)

Citations (2)

• 2012
  • 2012-10-01 GB GB201217522A patent/GB201217522D0/en not_active Ceased
• 2013
  • 2013-03-28 WO PCT/GB2013/050824 patent/WO2013150277A1/fr not_active Ceased

Patent Citations (2)

Non-Patent Citations (11)

Also Published As

Similar Documents

Legal Events